Bjarne Bogen heads a group that studies how dysregulated T - B cell collaboration may cause autoimmune disease and cancer and have projects within tumor immunology. Bogen also heads K.G. Jebsen Centre for Research on Influenza Vaccines.
About the group
The Bogen group and collaborators have over the last 25 years painstakingly established a novel type of interaction between T and B lymphocytes where T cells recognize Ig variable region-derived idiotypic (Id) peptides presented on the Major Histocompatibility Class II molecules on the surface of B cells. When the B cell receive help from such Id-specific T cells, and the B cell at the same time recognise a self antigen with it’s B cell receptor for antigen, the B cell, receiving these two serrate signals, will be activated, proliferate and differentiate.
Previous work has shown that this mechanism may cause immune dysregulation, autoimmunity and B lymphoma development in mouse models. The group is extending their studies of the basic mechanisms and are also making efforts to study this pathogenic mechanism in patients with Chronic Lymphatic Leukemia (CLL) and systemic Lupus Erythematosus (SLE).
The Bogen group also develops novel vaccines, known as Vaccibodies, against cancer and infectious disease including influenza, HIV and tuberculosis.
From May 2013, vaccinology projects and involved staff are organized by the K.G. Jebsen Centre for Research on Influenza Vaccines and are no longer part of CIR.
Researchers in the Bogen group also have an interest in anti-tumor immunology and and in particular how CD4+ T cells reject MHC class II negative tumor cells.
The Bogen group is part of the Department of Immunology at UiO and OUS and is located at OUS-Rikshospitalet.
Within CIR, the Bogen group runs projects within two areas:
- Idiotype-driven T-B collaboration and its role in health and disease
- The mechanism by which CD4+ T cells can reject cancer cells.
These two research topics may at first glance seem separate but are in fact closely related. The common theme is immunoglobulins and how these may be recognised by T cells.
Read more about the experimental model of autoimmunity.
- Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood. 2012 Mar 1;119(9):2176-7.
- Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schunemann N, Jundt F, Lindeberg MM, Bogen B. A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allowas Noninvasive Spatiotemporal Detection of Osteolytic Disease. PloS-ONE, 2012, 7:12.
- Lorvik KB, Haabeth OAW, Clancy T, Bogen B, Corthay A. Molecular profiling of tumor-spcific Th1 cells activated in vivo. Oncoimmunology, 2013, 2:5, e24383 1-12.
- Haabeth OAW, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumor-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011 Mar;2:240.
- Zangani MM, Frøyland M, Qui GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B. Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J.Exp.Med. 2007, 204:1189-91.